Insulet (PODD) said Wednesday that a randomized controlled trial showed its Omnipod 5 automated insulin delivery system led to improved glycemic control, including an average 0.8% reduction in HbA1c levels after three months compared with multiple daily injections with a continuous glucose monitor.
Among those with a baseline HbA1c above 8.0%, the reduction was 1.0%. Omnipod 5 users also spent an average of 5.4 more hours per day with glucose levels in the target range of 70 to 180 mg/dL without an increase in hypoglycemia.
The study evaluated the direct transition from multiple daily injections to Omnipod 5 in adults and children with type 1 diabetes who were not meeting glycemic targets. Conducted across 19 sites in France, the UK, and Belgium, it included 188 participants aged 4 to 70 years.
No cases of severe hypoglycemia or diabetic ketoacidosis were reported, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.